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Summary
 
The control of CD4 expression is essential for proper T lymphocyte development. We have
previously described a cis-acting silencer element required for repressing transcription of the
CD4 gene. Here we report the cloning and characterization of a novel factor that binds to a
critical functional site in the CD4 silencer. This factor, referred to as silencer-associated factor
(SAF), is a member of the helix-turn-helix factor family and shares sequence similarity with the
homeodomain class of transcriptional regulators. Introduction of a specific mutation into the
SAF binding site in the CD4 silencer abrogates silencer activity in transgenic mice, supporting
the hypothesis that SAF is important in mediating silencer function. Although SAF is expressed
in all lymphocytes, immunofluorescence studies indicate that SAF is present primarily in the
cytoplasm in T cells in which the endogenous silencer is nonfunctional, whereas it is present
primarily in the nucleus in T cells in which the silencer is functional. We thus hypothesize that
the subclass-specific subcellular compartmentalization of SAF plays an important role in medi-
ating the specificity of function of the CD4 silencer during T cell development.
Key words: transcriptional silencer • T cell development • subcellular localization
 
T
 
he control of CD4 coreceptor expression on developing
T lymphocytes is tightly regulated and linked to the
molecular events that drive repertoire selection (1–3). Ex-
pression of the CD4 gene is controlled by at least five distinct
transcriptional control elements, including the promoter,
three enhancers, and a silencer (4–15). The silencer is the
critical controlling element that downregulates CD4 tran-
scription at several stages of T cell development (7, 8, 11).
During thymopoiesis, the CD4 silencer initially represses
CD4 transcription in the CD4
 
2
 
CD8
 
2
 
 double negative
(DN)
 
1
 
 thymocyte, the most immature T cell precursor, and
ceases function as the DN thymocyte continues to develop
and expresses CD4. CD8, a similar coreceptor molecule, is
also expressed at this stage; the resulting CD4
 
1
 
CD8
 
1
 
 double
positive (DP) thymocyte then undergoes the T cell reper-
toire selection processes (16, 17). Surviving T cells can either
maintain expression of CD4 and become CD4
 
1
 
CD8
 
2
 
MHC class II–restricted T cells, which are primarily Th cells,
or they can downregulate CD4 and become CD4
 
2 
 
CD8
 
1
 
T cells, which are primarily cytotoxic T (Tc) cells. The latter
fate decision requires the reinitiation of function of the CD4
silencer and the repression of CD4 transcription. Because the
function of the silencer is tightly linked to these cell fate de-
cisions, a study of the nuclear factors that bind to the silencer
and mediate its function will provide insight into the molec-
ular mechanisms that drive these processes.
We have previously identified three factor binding sites
in the CD4 silencer, which we refer to as S1, S2, and S3
(11). Although all three sites are important for full silencer
function, there is significant redundancy; silencer activity is
only abrogated when S2 is deleted in combination with de-
letions in either S1 or S3. Using biochemical techniques,
we determined that nuclear factors bind specifically to each
of these sites (11). We have recently reported that the
lin12/Notch pathway intermediate HES-1 binds to S1 (18)
and the hematopoietic-specific transcription factor c-Myb
binds to S2 (reference 19 and Adlam, M., R.D. Allen, and
G. Siu, manuscript submitted for publication); however, the
factor(s) that bind to S3 and help mediate silencer function
is (are) unknown. Here we report the identification and
characterization of a novel homeodomain-like transcription
factor, silencer-associated factor (SAF), which binds to the
S3 region. Using transgenic reporter assays, we determined
that the specific SAF binding site within the S3 region is
important in silencer function, indicating that SAF may
indeed mediate CD4 silencer function. Although SAF is
 
1
 
Abbreviations used in this paper:
 
 DN, double negative; DP, double positive;
EMSA, electrophoretic mobility shift assay; EXD, Extradenticle; GST,
glutathione 
 
S
 
-transferase; HHTH, helix-helix-turn-helix; HTH, helix-
turn-helix; ORF, open reading frame; SAF, silencer-associated factor; SP,
single positive; Tc, cytotoxic T cell. 
282
 
Subclass-specific Nuclear Localization of SAF
 
expressed in all lymphocytes, immunofluorescence studies
indicate that in cells in which the CD4 silencer is nonfunc-
tional, such as CD4
 
1
 
CD8
 
1
 
 DP and CD4 single positive (SP)
T cells, endogenous SAF is preferentially localized in the
cytoplasm. Conversely, in cells in which the CD4 silencer
is functional, such as CD4
 
2
 
CD8
 
2
 
 DN and CD8 SP T cells,
endogenous SAF is present in the nucleus. These observa-
tions indicate that the selective transport of SAF from the
cytoplasm to the nucleus may be one mechanism for gen-
erating the functional specificity of the CD4 silencer.
 
Materials and Methods
 
Electrophoretic Mobility Shift Assays and Competitions.
 
Nuclear and
whole-cell extracts were purified from the different cell lines and
electrophoretic mobility shift assay (EMSA) analyses were con-
ducted as previously described (11). For the cold competition
experiments, 100- or 300-fold molar excess of nonradioactive
oligonucleotides were added to the binding mix without the
radioactive probe and incubated at room temperature for 20 min.
The radioactive probe was added, and then the EMSA was car-
ried out. For production of the glutathione 
 
S
 
-transferase (GST)–
SAF fusion protein, we used the pGEX2T system (Amersham
Pharmacia Biotech). The pGEX2TSAF plasmid contains a 0.7-kb
fragment containing the SAF cDNA obtained from our library
screen cloned into the pGEX2T GST vector inserted in frame
with the GST coding region. Purification of the GST–SAF fusion
protein in the DH5
 
a
 
 bacterial strain was conducted according to
the manufacturer’s instructions (Amersham Pharmacia Biotech).
For antibody ablations, the extracts were preincubated for 30 min
on ice with 0.5 
 
m
 
g of the appropriate antibody before completing
the EMSA reaction.
 
Yeast One-hybrid Screening.
 
The basic protocol used for yeast
one-hybrid screening has been described previously (20–22). Be-
cause of the large number of false positives obtained with this pro-
cedure, we designed a screen–counterscreen procedure to more
easily identify the true positives. The lacZ reporter plasmids,
pWK151, pWK153, and pWK154, were constructed by inserting
fourfold multimerizations of the 56bp S3 region, the 18bp S2 re-
gion, or the pKs linker, respectively, into pJL638 (reference 22;
gift of Dr. Joachim Li, University of California, San Francisco).
These plasmids were integrated into the genome of yeast strain
YJL 321 (reference 22; gift of Dr. Joachim Li), forming the YWK
101, YWK 102, and YWK 103 yeast strains, respectively. The
plasmid pWK 152 was constructed by inserting the S3 four-mer
into pJDM 373, which contains the HIS3 gene under the tran-
scriptional control of a TATA box (reference 23; gift of Dr. Ran-
dall Reed, Howard Hughes Medical Institute, Johns Hopkins
University School of Medicine, Baltimore, MD). A dual reporter
yeast strain was then constructed by transforming pWK 152 into
yeast strain YWK 101; this strain thus contains both the HIS3 and
lacZ reporter genes under the transcriptional control of a TATA
box and the four-fold multimerization of S3. The yeast strains
YJL 365 and YJL 363 containing lacZ plasmids under the tran-
scriptional control of multimerizations of either wild-type or mu-
tant ACS sites, respectively, were obtained from Dr. Joachim Li
(22). A WEHI-3 cDNA library constructed into the pGADNOT
vector was transformed into the YWK 101 yeast strain as previ-
ously described (24). 3 
 
3
 
 10
 
6
 
 transformants were grown on LEU
 
2
 
HIS
 
2
 
TRP
 
2
 
 3-AT plates and subjected to an XGAL screen. Sur-
vival of transformants in the absence of leucine and tryptophan is
due to the 
 
LEU2
 
 gene present in the library vector and the 
 
TRP1
 
gene present in pWK 151; clones encoding putative S3 binding
factors were identified using 3-AT and XGAL selection. The li-
brary plasmid DNA from these initial positives was then purified
and subsequently transformed into yeast strains YWK 101, YWK
102, YWK 103, YJL 365, and YJL363, and an XGAL screen was
performed. Library vectors that encode for a true S3 binding factor
turn blue only when transformed into YWK 101, and remain white
when transformed into YWK 102, 103, YJL 363, and YJL 365.
 
Antisera Preparation and Western Blot Analyses.
 
The rabbit anti-
SAF antisera was generated against the GST–SAF fusion protein
by BABCO. Antibodies against the GST moiety were removed
by batch purification with GST-coupled beads and the serum was
subsequently purified using Protein A–Sepharose (Amersham
Pharmacia Biotech). For the immunofluorescence studies, the
anti-SAF antisera was further purified by passing the GST-
adsorbed SAF antisera through a GST–SAF-coupled Hi Trap
 
R
 
-
 
N
 
-hydroxysuccinimide activated column (Amersham Pharmacia
Biotech) according to the manufacturer’s instructions. Bound
antisera was eluted by high and low pH cycles, and fractions
containing antibody were pooled, dialyzed against PBS, and con-
centrated by running on a protein A–Sepharose column (Amer-
sham Pharmacia Biotech). To determine the levels of SAF ex-
pressed in the cell lines, whole cell extracts were generated by
lysing 5 
 
3
 
 10
 
7 
 
cells in NP-40 lysis buffer for 60 min on ice. The
extracts were then pelleted, and supernatant was collected. 20 
 
m
 
g
of whole cell extracts from each cell line were loaded on a 12.5%
SDS polyacrylamide gel and run at 15 mA for 4 h. Transfer to ni-
trocellulose membrane was conducted according to manufacturer’s
instructions (Bio-Rad). For detection, anti-SAF serum was used
at 1:500 dilution and anti–
 
b
 
-Actin (Sigma Chemical Co.) at 1:1,000;
blots were developed with the BM Chemiluminescence kit
(Boehringer Mannheim) as described by the manufacturer.
 
Transgenic Experiments.
 
The pTG
 
D
 
2, pTG
 
D
 
3, and pTG
 
D
 
2-3
transgenic constructs and mice were described previously (11).
The pTG
 
D
 
2-3m4 construct is identical to pTG
 
D
 
2 except the M4
site specific mutation was placed in the S3 region as described
previously (reference 11 and see Fig. 1 for sequence). Founder
mice were generated by the Columbia-Presbyterian Cancer Cen-
ter Transgenic/Chimeric Mouse Facility. The following antibod-
ies were used to stain peripheral blood: FITC-conjugated GK1.5
(CD4), allophycocyanin-conjugated 53-6.7 (CD8) and ME1 (mouse
IgG1 anti–HLA-B7) followed by PE-conjugated goat anti–mouse
IgG1 (Caltag Labs.). Dead cells were excluded from analysis using
propidium iodide. Multiple founders were generated and ana-
lyzed; representative data are shown. Cells were analyzed on a
FACStar
 
PLUS
 
™
 
 flow cytometer (Becton Dickinson) using the Flo-Jo
and CELLQuest™ data analysis software at the Flow Cytometry
Facility at the Cancer Center of Columbia University.
 
Immunofluorescence Studies.
 
Immunofluorescence studies on the
CD4 SP Th clone D10, the CD4
 
1
 
CD8
 
1
 
 thymoma AKR1G1, the
CD4
 
2
 
CD8
 
2
 
 DN thymoma S49, and the CD8 SP Tc clone L3
were carried out as described previously (25). 10
 
7
 
 cells were cooled
on ice, washed once in cold PBS, and fixed by resuspension for
30 min on ice in 1 ml of 
 
2
 
20
 
8
 
C methanol. Fixed cells were then
washed two times in cold PBS and incubated on ice with either
affinity-purified SAF antisera or preimmune sera at a concentra-
tion of 2 
 
m
 
g/ml in 250 
 
m
 
l of PBS/5% sheep serum for 1 h. After
incubation with the primary antibody was completed, cells were
washed three times in cold PBS and incubated with Cy3-conju-
gated sheep anti–rabbit IgG (Sigma Chemical Co.) at a dilution
of 1:300 in 250 
 
m
 
l of PBS/5% sheep serum for 30 min. Cells were
then washed three times in cold PBS before mounting on poly-
 
l
 
-lysine–coated slides (Sigma Chemical Co.). Nuclear staining 
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was performed by adding DAPI to one of the final washing steps.
Microscopy was performed on a Leitz fluorescent microscope.
 
Results
 
Sequence Specificity of the S3 Binding Factor.
 
In previous
studies, we identified three factor binding sites in the CD4
silencer using DNAse footprinting. Additional EMSA anal-
yses identified one major and several minor factor–DNA
complexes when the footprinted S3 region was used as a ra-
dioactive probe; we have concentrated our further analyses
on the major S3 binding complex (11). Using 
 
o
 
-phenanthro-
line copper footprinting, we narrowed the recognition site
of the major S3 binding factor to a 16-bp region (reference
11 and Fig. 1). This region contains a 5-bp direct repeat
(CTGTG) separated by 6 bp. A comparison of this 16-bp
region with known binding site motifs revealed consensus
LEF-1 (26–29) and ETS (30) recognition sites; however,
we were unable to demonstrate that either LEF-1 or an ETS
family protein binds to S3 using biochemical approaches
(data not shown). To identify a more precise recognition
site for the major endogenous S3 binding factor, we de-
signed a series of mutant S3 oligonucleotides to be used as
competitors in EMSAs (Fig. 1 A). As we have reported
previously (11), we can detect a major DNA–protein com-
plex with the 16-bp S3 probe using nuclear extracts iso-
lated from CD4
 
2
 
CD8
 
1
 
 Tc cells; complex formation can be
completely inhibited by the addition of nonradioactive S3
probe but not linker, indicating that the S3 binding factor
binds specifically to the S3 probe (Fig. 2 A). Oligonucleo-
tides that contain mutations in both CTGTG repeats failed
to compete away the major S3 binding complex (Figs. 1 and
2, M1 and M4). However, those containing mutations in
either of the CTGTG repeats are still capable of competing
for S3 complex formation (Figs. 1 and 2, M5 and M6).
Oligonucleotides that contain mutations in sequences be-
tween the two CTGTG repeats also compete for complex
formation efficiently (Figs. 1 and 2, M3; Fig. 1, M2; and
data not shown); oligonucleotides that contain mutations in
the spacer sequence directly adjacent to the CTGTG re-
peats also compete for complex formation, albeit somewhat
less efficiently than do oligonucleotides with central muta-
tions (Figs. 1 and 2; compare M7 to M2 and M3). We can
detect three complexes with the S3 probe; the two slower
mobility complexes appear to have similar sequence speci-
ficities and thus may represent modified versions of the
same factor, whereas the fastest mobility complex does not
appear to be reproducible from experiment to experiment
(Fig. 2 A and data not shown). We can also detect S3 bind-
ing complexes in whole cell extracts purified from the D10
(CD4
 
1
 
CD8
 
2
 
 Th), S49 (DN thymoma), AKR1G1 (DP
thymoma), and the L3 and B18 (CD4
 
2
 
CD8
 
1
 
 SP Tc) T cell
Figure 1. Sequence of CD4 silencer S3. Sequence of the complete
probe used in the EMSA experiments is shown in the top line. SAF rec-
ognition sites are indicated by boxes. Sequence of mutant oligonucleo-
tides used in EMSA competition analyses are shown below; substitutions
from the wild-type sequence are indicated in bold.
Figure 2. EMSAs using the S3 probe and CD8 SP Tc L3 nuclear ex-
tracts (A), whole cell extracts from the CD4 SP Th clone D10, the DP
thymoma AKR1G1, and the DN thymoma S49 (B), or whole cell ex-
tracts from D10 and L3 (C). Arrows indicate putative SAF-containing
complex; addition of increasing amounts of different nonradioactive com-
petitor oligonucleotides are indicated above each lane. 
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clones (Fig. 2, B and C, and data not shown). Our data
thus indicate that S3 binding proteins are present in T cells
of all developmental phenotypes and bind to one of the
two CTGTG direct repeats in the S3 probe.
 
Cloning of a Novel S3 Binding Factor.
 
We next attempted
to clone a cDNA encoding the S3 binding factor using a
modified protocol of the previously published yeast one-
hybrid technique (see Materials and Methods for details).
We screened 3 
 
3 
 
10
 
6
 
 colonies and identified one positive
clone encoding a 0.7-kb cDNA. Using Northern blot anal-
yses with the cDNA as a radioactive probe, we can detect a
single 3.1-kb mRNA species in a wide variety of different
tissues (data not shown). We isolated a full-length 3.1-kb
cDNA clone by using the 0.7-kb cDNA as a radioactive
probe to screen a 
 
l
 
 phage thymus cDNA library. The cDNA
contains a 2,123-bp 5
 
9
 
 untranslated region and a 623-bp 3
 
9
 
untranslated region, as well as a 369-bp open reading frame
(ORF) that potentially encodes for a 123-amino acid pro-
tein with a mol mass of 14 kD (Fig. 3 A and data not
shown). We believe this ORF to be the one used in vivo
for five reasons. First, this ORF is used in the GAL4 fusion
protein originally isolated from the one-hybrid screen; sec-
ond, GST fusion proteins containing this ORF are able to
bind S3 specifically in EMSA analyses (see below); third, an
antisera raised against the same GST fusion protein is able
to recognize the S3 binding factor in T cell extracts (see
below); fourth, Western blot analyses on both cell lines and
tissues using this antisera identify one prominent 14-kD
species (see below); and fifth, using databank searches we
have identified a putative 
 
Caenorhabditis elegans
 
 homologue
(see below). In addition, in vitro transcription/translation
assays with the full-length cDNA produce a single 14-kD
species that can be recognized by this antisera on Western
blot analysis (data not shown). We refer to the novel tran-
scription factor encoded by the cDNA as silencer-associ-
ated factor, or SAF.
We conducted BLAST homology searches using the
translated protein sequence and could not identify signifi-
 
cant sequence similarity with known proteins. Expressed
sequence tagged cDNA sequences encoding portions of SAF
were identified in several libraries, including those con-
structed from RNA purified from diverse tissues, such as
thymus, 2-d embryo, and brain, further indicating that SAF is
expressed in a wide variety of tissues at different stages of
development. Interestingly, we have identified a putative
homologue for SAF in 
 
C. elegans
 
 using databank searches.
SAF shares an overall amino acid sequence identity of 32%;
however, the similarity is highest in the COOH-terminal re-
gion, where a 21-amino acid domain located just NH
 
2
 
-termi-
nal to the HHTH (helix-helix-turn-helix) domain shares 86%
identity at the amino acid level (18 out of 21), with 96% sim-
ilarity (20 out of 21) with its putative 
 
C
 
.
 
 elegans
 
 homologue
(boxed sequence, Fig. 3 A). However the exact function of
this 
 
C
 
.
 
 elegans
 
 ORF is unknown. These data indicate that
SAF may be conserved throughout evolution, further sup-
porting the hypothesis that SAF is an important factor.
 
SAF Shares Sequence Similarity with Homeodomain Pro-
teins.
 
Motif analyses indicated that the COOH-terminal
portion of SAF has a predicted HHTH structure. The helix-
turn-helix (HTH) motif is a common DNA binding do-
main that has been characterized for many different tran-
scription factors (31, 32). Based on the sequence similarity
in the DNA binding helix, there are six major families of
HTH proteins; SAF has the highest sequence similarity with
members of the homeodomain HTH family (Fig. 3 B). The
homeodomain proteins consist of a wide variety of differ-
ent transcription factors that are important in the control of
gene expression during development. All members of this
family have the same general structure: a three-
 
a
 
 helix
bundle with each helix separated by short amino acid turns,
and an NH
 
2
 
-terminal arm that stretches into the minor
groove (Fig. 3 B) (32, 33). Computer structural analysis of
SAF indicates 
 
a
 
-helical structures encompassing the gluta-
mine- and glutamic acid–rich domain representing helix
 
a
 
1 as well as the helix 
 
a
 
2 region (Fig. 3 B). The greatest
sequence similarity is within the putative DNA recogni-
Figure 3. (A) Protein translation of the SAF
ORF. Arrowhead indicates the beginning of the
sequence of the original yeast one-hybrid clone iso-
lated in the screen. (B) Sequence alignment of the
putative HTH domain of SAF with the HTH re-
gions of different homeodomain proteins. The
three putative a-helical structures are indicated
above; sequence similarity in the DNA recognition
helix (HR) is indicated in bold. 
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tion helix (helix 
 
a
 
3), including a stretch of amino acids
QVKLWVK that are seen often in the same position in ho-
meodomain proteins (Fig. 3 B, bold sequence). Although
SAF shows the greatest sequence similarity to the homeo-
domain proteins, there is a major difference between SAF
and the homeodomain protein family: all homeodomain
proteins have an asparagine at position 10 of 
 
a
 
3, whereas
SAF has a methionine (Fig. 3 B). As this region is believed
to be important in DNA sequence recognition, these ob-
servations indicate that SAF is likely to bind to DNA in a
manner distinct from the classical homeodomain–DNA in-
teraction.
 
Endogenous SAF Binds to S3 of the CD4 Silencer.
 
To con-
firm  that the SAF cDNA isolated from the yeast one-hybrid
screen binds S3, we generated a GST–SAF fusion protein
to be used in EMSAs. The SAF-encoding cDNA that was
isolated in the yeast one-hybrid screen was excised from
the yeast one-hybrid vector and subcloned into the pGEX2T
GST vector (Amersham Pharmacia Biotech); the cDNA
encompassed the COOH-terminal 34 amino acids that
contain the putative helix 
 
a
 
2 and helix 
 
a
 
3 of the HTH
domain (referred to as SAF89–123). The GST–SAF89–123
fusion protein was then used in EMSA analyses with dif-
ferent radioactive probes. We can detect a single DNA–
protein complex when we conduct EMSA analyses with
GST–SAF89–123 and the S3 probe (Fig. 4). This complex
formation is not contingent upon the GST moiety, since
purified GST alone cannot bind S3 (Fig. 4 A). The com-
plex formation is specific for the S3 sequence as it can be
inhibited with addition of nonradioactive S3 but not with
linker, and it cannot bind to oligonucleotide probes taken
from S1 or S2 of the CD4 silencer (Fig. 4 A). These data
indicate that SAF can bind to S3 in a sequence-specific
fashion. In addition, these data indicate that the DNA
binding domain of SAF is in the COOH-terminal in the
same region as the HTH motif, thus providing additional
evidence that HTH motif contains at least a portion of the
DNA binding domain. To determine if SAF has the same
fine specificity of binding as the endogenous S3 binding
factor, we conducted competition EMSAs with the S3
probe and the mutant oligonucleotide probes used above
(Figs. 1, 2, and 4). Similar to what we observed for the en-
dogenous S3 binding factor, an oligonucleotide that con-
tains mutation in both CTGTG repeats (M1) does not
compete for SAF binding to S3, whereas mutations in the
spacer sequence (M2 and M3) or only in one CTGTG re-
peat (M5 and M6) compete effectively for complex forma-
tion (Fig. 4 and data not shown). Thus, SAF has the same
DNA binding fine specificity as the endogenous S3 binding
factor, supporting the hypothesis that SAF is the endog-
enous S3 binding factor.
To characterize SAF in greater detail, we generated a
rabbit polyclonal antisera against SAF using the GST–
SAF89–123 fusion protein as antigen. The specificity of the
antisera was tested by Western blot analyses using whole
cell extracts purified from a variety of cells of different phe-
notypes (Fig. 5 A). We can detect the induction of expres-
sion of a 14-kD species in 293T cells transfected with a
CMV expression vector containing the full-length SAF
cDNA, supporting the hypothesis that the 369-bp ORF is
indeed the reading frame used in vivo (Fig. 5 A). In addi-
tion, we can detect the same 14-kD species in all T cell
subclasses, B cells, macrophages, and fibroblasts (Fig. 5 A),
indicating a wide tissue distribution of expression of SAF
protein, consistent with the EMSA data discussed above.
To prove that the endogenous S3 binding protein is indeed
SAF, we tested whether the SAF antisera would affect en-
dogenous S3 binding factor–DNA complex formation in
EMSAs. As can be seen in Fig. 5 B, we can ablate S3–pro-
tein complex formation completely in both CD4 SP Th
and CD8 SP Tc cell extracts using the SAF antisera. We
cannot inhibit S3–protein complex formation significantly
using either the preimmune sera or an antibody directed
against Elf-1, indicating that this ablation is specific for the
endogenous S3 binding protein. These data indicate that
the endogenous S3 binding protein shares antigenic epi-
topes with SAF, supporting the hypothesis that SAF is the
endogenous S3 binding factor.
Figure 4. Sequence specificity of the
SAF DNA binding domain. (A) EMSAs
using the GST–SAF89–123 fusion pro-
tein and CD4 silencer S1, S2, and S3
probes. Probe, titration of nonradioac-
tive competitor oligonucleotides, and
protein extract used are indicated above
lanes. Arrow indicates SAF–DNA com-
plex. (B) Competition EMSAs using
the GST–SAF89–123 fusion protein,
the S3 probe, and S3 mutant variants.
Titrations of different nonradioactive
competitor mutant S3 oligonucleotides
are shown above lanes. Arrow indi-
cates SAF–DNA complex. 
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Although the original S3 deletion removed the SAF
binding site, this deletion encompassed 56 bp, so it is possi-
ble that the SAF binding site is irrelevant and that other se-
quences within S3 are required for silencer function. To de-
termine if the SAF binding site itself is important in silencer
function, we generated a mutant silencer, Sil
 
D
 
2-3m4, that
contains the 18-bp S2 deletion and the M4 mutation of the
SAF binding site. The M4 mutation completely abrogates
SAF binding as defined by our biochemical data (see above).
This mutant silencer was cloned into the pTG reporter
construct, transgenic mice were generated, and peripheral
T cells were harvested from expressing founders and ana-
lyzed for expression of the HLA-B7 marker gene (Fig. 6
and data not shown). Similar to the pTGSil
 
D
 
2-3 transgenic
mice, both CD4 SP and CD8 SP peripheral T cells in the
pTGSil
 
D
 
2-3m4 transgenic mice express the marker gene,
indicating that silencer function is abrogated (Fig. 6 B).
These data indicate that the site-specific mutation of the
SAF binding site is functionally similar to the original 56-bp
deletion of S3, which in combination with a deletion in S2
leads to abrogation of silencer function. Therefore, we can
correlate the loss of SAF binding to S3 with the loss of si-
lencer function, supporting the hypothesis that SAF is in-
deed playing an important role in CD4 silencer function.
 
Subcellular Compartmentalization of SAF.
 
As mentioned
above, SAF is expressed in T cells of all developmental
phenotypes. The fact that the CD4 silencer functions in
CD4
 
2
 
 but not CD4
 
1
 
 cells indicates that the specificity of
silencer function cannot be mediated by cell type–specific
SAF expression. Therefore, if SAF plays a role in the speci-
ficity of silencer function, we predict that there are post-
translational events that permit SAF to function only in
 
The SAF Binding Site Is Important for CD4 Silencer Func-
tion.
 
Our biochemical data indicate that SAF binds to an
important functional region of the CD4 silencer, indicating
that SAF is playing a role in silencer function. Should this
be the case, we can predict that we would abrogate CD4
silencer function by making a site-specific mutation in the
SAF binding site. To test this, we generated mutant silenc-
ers and tested them in transgenic assays (Fig. 6). We have
previously shown that single deletions of any of the three
factor binding sites in the CD4 silencer, referred to as S1,
S2, and S3, do not affect silencer activity. In fact, silencer
function is abrogated only when S2 is deleted in conjunc-
tion with deletions in either S1 or S3 (11). We have gener-
ated a series of mice transgenic for constructs that contain
silencers with different combinations of factor binding site
deletions (11). The base pTG construct contains the HLA-B7
marker gene under the transcriptional control of the CD4
promoter and enhancers; the pTGSil series constructs also
contain either the unmutated silencer or mutated silencers
(11). The pTGSil
 
D
 
2 construct contains the silencer with an
18-bp deletion of the S2 region, the pTGSil
 
D
 
3 construct
contains the silencer with a 56-bp deletion of the S3 region
including the SAF binding site, and the pTGSil
 
D
 
2-3 con-
struct contains the silencer with both deletions. As can be
seen in Fig. 6 A, cells that express the HLA-B7 marker gene
in the pTGSil
 
D
 
2 and pTGSil
 
D
 
3 transgenic mice are con-
fined to the peripheral CD4 SP T cell population, as would
be expected if silencer function is intact. In contrast, the
pTGSil
 
D
 
2-3 transgenic mice express the marker gene in
both CD4 SP and CD8 SP T cells, indicating that silencer
function has been abrogated. As discussed above, these ob-
servations are consistent with our previous data (11).
Figure 5. Expression and bind-
ing of endogenous SAF. (A) West-
ern blot analysis with the SAF
antisera (top) and the control
anti–b-actin antibody (bottom).
Western blot analysis on whole
cell extracts from 293T cells (lane
1): 293T cells transfected with 5,
10, and 20 mg of the CMV–SAF
expression construct (lanes 2–4);
the CD41CD81 DP AKR1G1
thymoma (lane 6); the CD81 SP
Tc L3 cell clone (lane 7); the
CD41 SP Th D10 cell clone (lanes
8 and 9); the P3X63 plasmacytoma
(lane 10); the 103 pre-B cell lym-
phoma (lane 11); the WEHI-3B
macrophage/monocyte (lane 12);
and the 3T3 fibroblast (lane 13).
Molecular weight standards were
loaded in lane 5. (B) Antibody ab-
lation EMSA analyses with the
SAF antisera and (left) CD41 SP
Th D10 or (right) CD81 SP Tc
L3 extracts. Lanes containing S3
probe only, S3 probe with ex-
tract, and S3 probe with extract
and antibody are indicated above
each lane. ‘Pre’ indicates preim-
mune sera.287 Kim and Siu
CD42 cells, thus conveying specificity of silencer function.
One potential mechanism is the cell type–specific parti-
tioning of the factor in different subcellular compartments.
For example, it is possible that a ubiquitously expressed
transcription factor is sequestered outside of the nucleus to
prevent DNA binding. In the case of the CD4 silencer,
cells that express CD4 would localize SAF to the cyto-
plasm, thus preventing it from binding to the silencer and
inducing its function and therefore allowing CD4 tran-
scription. In cells that do not express CD4, SAF is trans-
ported to the nucleus, thus allowing SAF to bind to the si-
lencer and induce its function leading to the repression of
CD4 transcription. This hypothesis predicts that we would
detect SAF protein primarily in the nucleus in T cells that
do not express CD4 and primarily in the cytoplasm in T
cells that express CD4. To test this hypothesis, we used af-
finity-purified anti-SAF antisera in immunofluorescence
experiments with T cells of different developmental phe-
notypes (Figs. 7 and 8). Interestingly, the anti-SAF antisera
stains the cytoplasm of both the CD4 SP and the CD41
CD81 cells most intensely. As can be seen in Fig. 7, A and
D, the nucleus of each of these cells are present as a shadow
with only faint staining (nuclear membrane indicated with
thick arrowheads; compare panels A with B, and D with
E), whereas the ring of cytoplasm surrounding the nucleus
stains intensely (cell membrane indicated with thin arrows;
compare panels A with B and C, and D with E and F).
These observations correlate with the expression of CD4 in
these two T cell developmental subclasses; SAF is predomi-
nantly in the cytoplasm and thus cannot access its S3 bind-
ing site and help mediate silencer function. The preim-
mune sera yields only low levels of staining, indicating that
the signal detected is specific (Fig. 7, G–I).
In contrast, for the DN and CD8 SP T cells, anti-SAF
staining colocalizes with the nuclear DAPI stain, indicating
that for these CD42 T cell subclasses SAF is present at high
levels in the nucleus (Fig. 8; compare panels A with B, and
D with E). The localization of SAF to the nucleus in CD42
T cells correlates both with the expression of CD4 and en-
dogenous silencer function; in these cells, SAF is in the nu-
cleus and thus presumably has access to its cognate binding
site in the CD4 silencer, which will thus allow it to medi-
ate silencer function. Taken together, our data indicate that
SAF protein, although synthesized in T cells of all develop-
mental phenotypes, is preferentially localized in different
subcellular compartments depending on the expression of
CD4 and are consistent with the hypothesis that the devel-
opmental stage-specific subcellular localization of SAF plays
a role in the specificity of function of the CD4 silencer. In
contrast, immunofluorescence with antisera against both
c-Myb and HES-1, the other CD4 silencer binding factors,
indicate that both of these factors are nuclear in T cells of
all developmental phenotypes (data not shown), suggesting
that SAF may play a unique role in the control of CD4 si-
lencer function and CD4 transcription.
Discussion
SAF: A Novel CD4 Silencer Binding Protein. We have
identified a novel factor, which we refer to as SAF, that
Figure 7. Subcellular localization of SAF in CD41 SP and CD41CD81
T cells. Staining with the affinity-purified anti-SAF antisera (A and D),
DAPI (B and E) and the light-phase field (C and F) of the D10 CD4 SP
and the AKR1G1 CD41CD81 T cells are indicated. Each set of fields is
from the same experiment. G–I show staining with the preimmune se-
rum, DAPI, and light-phase field for a CD8 SP T cell; all other preim-
mune stainings for the other cell types showed similar patterns (data not
shown). Thick arrows indicate cell membrane, and thin arrows indicate
nuclear membrane.
Figure 6. Site-specific mutation of the SAF binding site in S3 leads to
abrogation of CD4 silencer function. Peripheral T cells were isolated
from the (A) pTGD2, pTGD2-3, and pTGD3 and the (B) pTGD2-3m4
transgenic lines and stained with antibodies to CD4, CD8, and the HLA-B7
marker. The HLA-B71 cells were then gated on and analyzed for expres-
sion of CD4 (y axis) and CD8 (x axis). Presence of transgenic marker–
positive CD8 SP T cells in the pTGD2-3m4 and pTGD2-3 mice (box,
lower right quadrant) indicate loss of silencer function in the marker con-
struct. Five different pTGD2-3m4 founders were generated; data from
representative high expressing (B, left) and low expressing (B, right) trans-
genic mice are shown.288 Subclass-specific Nuclear Localization of SAF
binds to a critical functional site of the CD4 silencer. We
have determined that endogenous SAF binds to S3 and
probably mediates silencer function; we draw this conclu-
sion on the basis of several different experimental ap-
proaches. First, we have established that the fine DNA
binding specificity of SAF is identical to that of the endog-
enous S3 binding factor. In addition, antisera raised against
SAF specifically ablate the formation of the endogenous S3
binding complex. Finally, in our transgenic reporter assay
system, a site-specific mutation in S3 that abrogates both
SAF and endogenous S3 factor binding also breaks CD4 si-
lencer function in conjunction with the S2 deletion. These
functional results are consistent with our earlier data, which
indicated that a large deletion in the S3 region, in combi-
nation with a deletion in the S2 region, abrogates silencer
function (11). Taken together, our data provide strong evi-
dence supporting the hypothesis that endogenous SAF binds
to the CD4 silencer at S3 and mediates its function.
SAF has several interesting structural features. The func-
tion of the NH2-terminal domain of SAF is unknown. How-
ever, SAF shares some sequence similarity with the home-
odomain class of transcription factors that are known to be
important both in transcriptional repression and in the con-
trol of developmentally-regulated genes (31, 32). In partic-
ular, the DNA binding domain of SAF contains an HHTH
motif similar to that of the homeodomain class of proteins.
There is significant sequence similarity between SAF and
homeodomain proteins in the DNA recognition helix, al-
though SAF lacks an important conserved asparagine at po-
sition 10 of helix a3. It is interesting to note that the SAF
binding site (CTGTGNNNNNNCTGTG) differs signifi-
cantly from the consensus homeodomain recognition se-
quence (TCAATTAAAT) (34, 35). The asparagine at posi-
tion 10 of helix a3 interacts via hydrogen bonds and van
der Waals interactions with a central adenine, a base that is
not present in the SAF recognition site (36). Thus, this as-
paragine-to-methionine change may reflect a difference in
the consensus recognition sequences between the two fac-
tors. Despite these sequence similarities, a complete struc-
ture analysis of SAF is required before we can draw defini-
tive conclusions about its relationship with the homeodomain
proteins.
We have been unable to reproduce CD4 silencer func-
tion in transfection assays by transfecting silencer-contain-
ing reporter constructs into CD4 SP and CD8 SP T cell
clones. Although the reasons for this are not known, sev-
eral possibilities exist. Perhaps the most likely is that si-
lencer function cannot be recapitulated using transfected
reporters because it requires higher order chromatin struc-
ture that is normally lacking in transfection systems. The
only reliable assay of silencer function is the transgenic re-
porter system (11), as this requires the insertion of the re-
porter construct into the genome, this observation is con-
sistent with this hypothesis. Alternatively, it may be that
SAF requires a non-DNA binding corepressor to mediate
transcriptional repression. For example, the Hairy family of
DNA binding factors require the non-DNA binding cofac-
tor groucho to mediate transcriptional repression (37); sim-
ilarly, the Ssn6-Tup1 complex serves as a general repressor
of transcription in yeast that is recruited to target promoters
by many different sequence-specific DNA binding proteins
(38). Finally, levels of SAF expressed during transient trans-
fection may exceed endogenous levels of post-translational
modification enzymes that might be required for its activ-
ity. In this latter case, most of the overexpressed SAF in
transfected T cells would be unable to mediate repression
due to lack of modification. In any case, the lack of a good
transfection system to study silencer function indicates that
further characterization of the role of SAF in mediating
CD4 silencer function will most likely require more com-
plicated mouse genetic experiments. For example, it may
be possible to generate altered specificity binding mutants
of SAF to study its function; similar experiments have been
conducted to characterize other mammalian transcription
factors (39, 40). In addition, generation of the targeted-dis-
ruption of the endogenous SAF gene will probably provide
useful information on the role of SAF in T cell develop-
ment and CD4 silencer function.
SAF and the Specificity of CD4 Silencer Function. Although
in genetic experiments the CD4 silencer is the critical con-
Figure 8. Subcellular localization of SAF
in CD81 SP and CD42CD82 T cells. Stain-
ing with the affinity-purified anti-SAF anti-
sera (A and D), DAPI (B and E), and the
light-phase field (C and F) of the L3 CD8 SP
and the S49 DN T cells are indicated. Each
set of fields is from the same experiment.289 Kim and Siu
trolling element that mediates the specificity of CD4 gene
expression during T cell development, all of the silencer
binding factors we have identified, including SAF, are ex-
pressed in T cells of all developmental stages (11, 18, 19).
However, our data indicate that although SAF is expressed
in all T cells, its subcellular localization differs in a T cell
subclass–specific manner. In cells that express CD4, the
CD4 SP, and the DP T cells, SAF localizes to the cyto-
plasm; whereas in cells that do not express CD4 (the DN
and CD8 SP T cells) SAF localizes to the nucleus. This is
the first report of biochemical subclass specificity of the fac-
tors that mediate CD4 gene expression and provide a po-
tential mechanism for the control of CD4 silencer function
during T cell development. We hypothesize that in cells in
which the CD4 silencer is functioning, such as the CD8 SP
and DN T cells, SAF is transported to the nucleus, where it
binds to S3 of the CD4 silencer and helps mediate its re-
pression of CD4 gene expression. In cells in which the si-
lencer is nonfunctional, such as the CD4 SP and DP T cells,
SAF is specifically excluded from the nucleus. Because of
this, SAF cannot bind to the CD4 silencer, and thus does
not mediate its function. This model indicates that the
mechanisms controlling SAF nuclear transport may be linked
to the processes that transmit the differentiation signal from
the surface of the thymocyte during the selection process.
The nature of the mechanism that restricts SAF localiza-
tion in specific cell types is unclear. Although SAF does not
have a consensus nuclear localization signal, its small size
should in principle permit it to migrate freely through the
nuclear pore, and thus some mechanism to compartmental-
ize it must be hypothesized. It is possible that the posttrans-
lational modification of SAF either allows or blocks its nu-
clear transport; a similar mechanism is used to initiate the
translocation of the cytoplasmic component of nuclear fac-
tor of activated T cells to the nucleus (41). Alternatively,
SAF may be bound to another factor, which causes SAF to
be sequestered in the cytoplasm; the posttranslational mod-
ification of the binding partner would then release SAF, al-
lowing it to be transported to the nucleus. Such a mecha-
nism is used to regulate the nuclear localization of nuclear
factor kB (42). Because SAF is a homeodomain-like pro-
tein, one particularly interesting example of transcription
factor translocation involves the Drosophila melanogaster fac-
tor Extradenticle (EXD). EXD is a homeodomain tran-
scription factor that mediates cell fate during embryonic
development (43). EXD is often found in the cytoplasm;
however, at specific stages of development, EXD binds to a
second homeodomain protein, Homothorax, which causes
the heterodimer to translocate to the nucleus (44, 45). Once
in the nucleus, the EXD–Homothorax heterodimer binds
to adjacent DNA recognition sites in the promoters of tar-
get genes and induces their expression. It is possible that
SAF is translocated specifically to the nucleus during T cell
development by a member of the Meis family, the mam-
malian Homothorax homologues. Interestingly, there is a
consensus Meis recognition site within the S3 region, di-
rectly adjacent to the SAF binding site; preliminary bio-
chemical experiments indicate that a nuclear factor in
CD42 T cells recognizes the Meis recognition site specifi-
cally (Sarafova, S., and G. Siu, unpublished data). It is thus
possible that, similar to EXD–Homothorax, Meis is shut-
tling SAF to the nucleus and binding as a dimer to their re-
spective recognition sites in the CD4 silencer. It is impor-
tant to note that for many promoters EXD requires its
Homothorax partner to mediate element function; thus,
should SAF require a partner for nuclear localization, it is
likely that it will also require this partner to mediate si-
lencer function. We are currently conducting experiments
to address these issues directly.
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